Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Muscle Invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Muscle Invasive Bladder Cancer
Related studies linked through entity extraction aliases.
Sample Collection for Ongoing Research and Product Evaluation Study
- Status
- RECRUITING
- Phase
- N/A
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
- Status
- RECRUITING
- Phase
- NA
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI
- Status
- COMPLETED
- Phase
- N/A
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Performance Evaluation of the C2i Test
- Status
- WITHDRAWN
- Phase
- N/A
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
- Status
- UNKNOWN
- Phase
- N/A
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
- Status
- COMPLETED
- Phase
- PHASE1
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2